

Monthly Report – September 2019

Fund description

FORTUNA Multi INDEX 10 is an investment fund under Swiss law in the «Other funds for traditional investments» category, and it is **income-oriented**. The investment goal is primarily to increase the fund's assets and produce stable results.

The fund invests a minimum of 51% of its assets in other collective investment schemes (target funds). The remaining 49% may be invested in equities and bonds, the equity portion must not exceed 20%.


The fund management company must also follow the investment rules in the Swiss Federal Law on Occupational Retirement, Survivors' and Disability Pension Plans (BVV2).

This fund is suitable for investors who would like to profit mainly from the return opportunities in the bond markets and partly also from share price gains.

Fund Facts

Name of fund	FORTUNA Multi INDEX 10
Funds manager	Fortuna Investment AG Andreas Resch / since 2018
Domicile of fund	Switzerland
Fund management	Fortuna Investment AG, Adliswil
Custodian bank	UBS Switzerland AG
Currency of fund	CHF
ISIN	CH0110739056
Securities no.	11 073 905
Bloomberg	FORM10 SW
Issuing commission	2.00%
Launch date	01 October 2010
Accounting year ends	31 March
Issue/redemption	daily
Reference Index	Customized Benchmark
Distribution	plowing back

Performance in CHF¹



in %	2015	2016	2017	2018	Sep. 2019
Fund (CHF)	-0.07	0.34	0.91	-2.04	-1.79
Ref. Index ²	1.49	1.87	2.41	-0.41	-2.12

¹ These figures refer to the past. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Source for all data and charts (if not indicated otherwise): UBS Asset Management

² Reference Index in currency of share class (without costs)

Fund assets (in mn.)	6.83
Net asset value (CHF, 30.09.2019)	113.72
Last 12 months (CHF)	– high 116.15 – low 105.42
Modified Duration (years)	7.70
Average remaining maturity (years)	n.a.
Flat fee	1.00%
Total expense ratio (TER) p.a.	1.09% ¹


¹ as at 31.03.2019

Customer service


Fund Administration
Soodmattenstrasse 10
8134 Adliswil, Switzerland
Phone: +41 58 472 53 06
E-mail: investment.ch@generali.com
Internet: www.fortunainvest.ch

Monthly Report – September 2019

Investment instrument exposure (%)



Currency exposure (%)



10 largest positions (%)

ISHARES Dom. Gov. Bonds 7-15 Y	17.4
ISHARES ETF CH Government Bonds 3-7 Y	9.7
CH Government Bonds 2029	8.7
CH Government Bonds 2028	8.6
CH Government Bonds 2031	8.4

CH Government Bonds 2030	8.3
ISHARES BARCLAYS 7-10 TREASURY	7.6
CH Government Bonds 2032	7.6
LYXOR UCITS ETF EUROMTS 7-10Y	6.1
UBS ETF SMI	5.1

Performance in CHF¹

in %	2019 YTD ²	LTD ³	1 year	2 years	3 years	4 years	5 years	10 years
Fund (CHF)	6.20	19.34	6.94	4.85	1.87	5.58	7.70	n.a.
Ref. Index ⁴	9.51	38.85	11.26	10.22	8.06	14.30	18.71	n.a.

¹ These figures refer to the past. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Source for all data and charts (if not indicated otherwise): UBS Asset Management

² YTD: year-to-date (since beginning of the year)

³ LTD: launch-to-date

⁴ Reference Index in currency of share class (without costs)

This document constitutes neither an offer nor a recommendation or an invitation from FORTUNA Investment AG to buy or sell investment instruments, carry out transactions or conclude any legal act. FORTUNA Investment AG is unable to guarantee (whether explicitly or implicitly) that the published information and opinions are accurate, complete and up to date. Historic performance data are no guarantee of future returns. The future performance of investments cannot be deduced from the indicated previous market developments, i.e. the value of an investment may fall as well as rise. FORTUNA Investment AG cannot guarantee that the value of the capital invested will be maintained (or indeed rise) as a result of price fluctuations. Please read the relevant sales prospectus for further information on sales restrictions.